Pharsight

Edluar patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597281 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia
Apr, 2027

(3 years from now)

US9265720 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia
Feb, 2031

(7 years from now)

Edluar is owned by Mylan Speciality Lp.

Edluar contains Zolpidem Tartrate.

Edluar has a total of 2 drug patents out of which 0 drug patents have expired.

Edluar was authorised for market use on 13 March, 2009.

Edluar is available in tablet;sublingual dosage forms.

Edluar can be used as method of treating insomnia characterized by difficulty with sleep onset.

The generics of Edluar are possible to be released after 25 February, 2031.

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Market Authorisation Date: 13 March, 2009

Treatment: Method of treating insomnia characterized by difficulty with sleep onset

Dosage: TABLET;SUBLINGUAL

How can I launch a generic of EDLUAR before it's drug patent expiration?
More Information on Dosage

EDLUAR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic